Vertex, Inc. (NASDAQ:VERX) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. Wall Street has a mixed ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...

Industry expert Ralf Gärtner joins as SVP and Regional Manager to spearhead Vertex’s global operationsLONDON, Oct. 30, 2025 ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares ...

SAN FRANCISCO—Vertex Pharmaceuticals is ready to do some deals. As the company looks to build on its momentum in cystic fibrosis, CEO Jeffrey Leiden said he's eyeing deals large and small—in CF and ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright ...

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.